Literature DB >> 19589874

Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.

Arik Dahan1, Hairat Sabit, Gordon L Amidon.   

Abstract

The purpose of this study was to thoroughly characterize the efflux transporters involved in the intestinal permeability of the oral microtubule polymerization inhibitor colchicine and to evaluate the role of these transporters in limiting its oral absorption. The effects of P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2), and breast cancer resistance protein (BCRP) inhibitors on colchicine bidirectional permeability were studied across Caco-2 cell monolayers, inhibiting one versus multiple transporters simultaneously. Colchicine permeability was then investigated in different regions of the rat small intestine by in situ single-pass perfusion. Correlation with the P-gp/MRP2 expression level throughout different intestinal segments was investigated by immunoblotting. P-gp inhibitors [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918), verapamil, and quinidine], and MRP2 inhibitors [3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK571), indomethacin, and p-aminohippuric acid (p-AH)] significantly increased apical (AP)-basolateral (BL) and decreased BL-AP Caco-2 transport in a concentration-dependent manner. No effect was obtained by the BCRP inhibitors fumitremorgin C (FTC) and pantoprazole. P-gp/MRP2 inhibitors combinations greatly reduced colchicine mucosal secretion, including complete abolishment of efflux (GF120918/MK571). Colchicine displayed low (versus metoprolol) and constant permeability along the rat small-intestine. GF120918 significantly increased colchicine permeability in the ileum with no effect in the jejunum, whereas MK571 augmented jejunal permeability without changing the ileal transport. The GF120918/MK571 combination caused an effect similar to that of MK571 alone in the jejunum and to that of GF120918 alone in the ileum. P-gp expression followed a gradient increasing from proximal to distal segments, whereas MRP2 decreased from proximal to distal small intestinal regions. Overall, it was revealed that the combined effect of P-gp and MRP2, but not BCRP, dominates colchicine transepithelial transport, leading to complete coverage of the entire small intestine, and makes the efflux transport dominate the intestinal permeability process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589874     DOI: 10.1124/dmd.109.028282

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

Authors:  Jonathan M Miller; Arik Dahan; Deepak Gupta; Sheeba Varghese; Gordon L Amidon
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.

Authors:  Richard A Graves; Grace A Ledet; Elena Y Glotser; Demaurian M Mitchner; Levon A Bostanian; Tarun K Mandal
Journal:  Eur J Pharm Sci       Date:  2015-04-28       Impact factor: 4.384

3.  Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.

Authors:  Vaibhav Mundra; Yang Peng; Virender Kumar; Wei Li; Duane D Miller; Ram I Mahato
Journal:  Drug Deliv Transl Res       Date:  2015-06       Impact factor: 4.617

Review 4.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  The fraction dose absorbed, in humans, and high jejunal human permeability relationship.

Authors:  Arik Dahan; Hans Lennernäs; Gordon L Amidon
Journal:  Mol Pharm       Date:  2012-05-04       Impact factor: 4.939

6.  Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.

Authors:  Tuba Incecayir; Yasuhiro Tsume; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

7.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

8.  The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Authors:  Arik Dahan; Avital Beig; Viktoriya Ioffe-Dahan; Riad Agbaria; Jonathan M Miller
Journal:  AAPS J       Date:  2012-12-15       Impact factor: 4.009

9.  Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine.

Authors:  Moran Fairstein; Rotem Swissa; Arik Dahan
Journal:  AAPS J       Date:  2013-02-26       Impact factor: 4.009

10.  In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.

Authors:  Olena Kis; Sharon L Walmsley; Reina Bendayan
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.